Search Results
Sep 03, 2026, 10:31 ET Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsight
Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui
More news about: DelveInsight Business Research, LLP
Jul 15, 2026, 10:31 ET Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight
Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui
More news about: DelveInsight Business Research, LLP
Jun 30, 2026, 09:00 ET AVEO Oncology Announces Succession Plan
patients with cancer.About AVEO Pharmaceuticals, Inc.AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib)
More news about: AVEO, an LG Chem company
May 26, 2026, 05:32 ET Soft Tissue Sarcoma with Lung Metastases Market Set to Expand Across the 7MM During the Forecast Period (2026-2036) with Advancing Targeted and Cellular Therapies | DelveInsight
Pharmaceuticals, Lytix Biopharma, Incyte Corporation, Daiichi Sankyo, NantPharma, Iovance Biotherapeutics, Agenus, Eli Lilly and Company, Adaptimmune, Aadi, AVEO Pharmaceuticals, Amgen, and others.
More news about: DelveInsight Business Research, LLP
May 05, 2026, 08:00 ET AVEO Oncology, an LG Chem company, Announces Two Poster Presentations at ASCO 2026 Annual Meeting
Saturday, May 30, 2026, 1:30 PM – 4:30 PM CDTAbout AVEO Pharmaceuticals, Inc.AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S.
More news about: AVEO, an LG Chem company
Apr 20, 2026, 09:33 ET Innovations Centered on 'A Better Life for Customers' Win at LG Awards
demonstrated the spread of an innovative organizational culture across borders through this year's top-prize winning projects. Penny Butler, Senior Director at AVEO Oncology, LG Chem's U.S. oncology subsidiary, was selected as the first international employee to win in the individual category of the 'Customer Impression
More news about: LG
Mar 12, 2026, 10:01 ET Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight
Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.About DelveInsightDelveInsight
More news about: DelveInsight Business Research, LLP
Mar 09, 2026, 17:31 ET Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, among others.
More news about: DelveInsight Business Research, LLP
Mar 02, 2026, 17:31 ET Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
and key liver cancer companies, including Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics,
More news about: DelveInsight Business Research, LLP
Feb 26, 2026, 17:31 ET Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight
Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui
More news about: DelveInsight Business Research, LLP
Feb 18, 2026, 09:00 ET AVEO Oncology, an LG Chem company, Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study
Springs, Spring BallroomAbout AVEO Pharmaceuticals, Inc.AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib)
More news about: AVEO, an LG Chem company
Jan 14, 2026, 10:45 ET AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab
Officer of Blood Cancer United. "Our collaboration with AVEO is a key next step for the trial and transforming patient care for adults with AML."About AVEO Pharmaceuticals, Inc.AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed
More news about: AVEO, an LG Chem company
Jan 14, 2026, 08:00 ET Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment
In collaboration with AVEO Oncology, an LG Chem company, ("AVEO") the new sub-study is evaluating ficlatuzumab, a monoclonal antibody targeting hepatocyte growth factor (HGF), in combination with
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Nov 27, 2025, 17:31 ET Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight
Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui
More news about: DelveInsight Business Research LLP
Nov 04, 2025, 09:00 ET AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound
About AVEO Pharmaceuticals, Inc. AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib)
More news about: AVEO, an LG Chem company
Oct 20, 2025, 17:31 ET Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight
Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui
More news about: DelveInsight Business Research, LLP
Oct 01, 2025, 09:00 ET Moneta Adds New Team with $262M AUM, Expanding Colorado Presence
Investment Advisors, LLC ("Moneta"), one of the nation's largest Registered Investment Advisors (RIAs), announced today that the Williams team from Aveo Capital Partners has joined Moneta as its newest partner team, further strengthening Moneta's Colorado footprint.
More news about: Moneta